TN2011000433A1 - Alpha -4-beta-7heterodimer specific antagonist antibody - Google Patents

Alpha -4-beta-7heterodimer specific antagonist antibody

Info

Publication number
TN2011000433A1
TN2011000433A1 TN2011000433A TN2011000433A TN2011000433A1 TN 2011000433 A1 TN2011000433 A1 TN 2011000433A1 TN 2011000433 A TN2011000433 A TN 2011000433A TN 2011000433 A TN2011000433 A TN 2011000433A TN 2011000433 A1 TN2011000433 A1 TN 2011000433A1
Authority
TN
Tunisia
Prior art keywords
beta
alpha
antagonist antibody
specific antagonist
specific
Prior art date
Application number
TN2011000433A
Other languages
English (en)
Inventor
Hailing Hsu
Ian Foltz
Taruna Arora
Frederick W Jacobsen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42224952&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000433(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of TN2011000433A1 publication Critical patent/TN2011000433A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
TN2011000433A 2009-03-20 2011-08-24 Alpha -4-beta-7heterodimer specific antagonist antibody TN2011000433A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16215409P 2009-03-20 2009-03-20
US30682910P 2010-02-22 2010-02-22
PCT/US2010/027422 WO2010107752A2 (fr) 2009-03-20 2010-03-16 Anticorps antagoniste spécifique d'un hétérodimère alpha-4-bêta-7

Publications (1)

Publication Number Publication Date
TN2011000433A1 true TN2011000433A1 (en) 2013-03-27

Family

ID=42224952

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000433A TN2011000433A1 (en) 2009-03-20 2011-08-24 Alpha -4-beta-7heterodimer specific antagonist antibody

Country Status (27)

Country Link
US (6) US8444981B2 (fr)
EP (1) EP2408816B1 (fr)
JP (3) JP5498566B2 (fr)
KR (2) KR101391472B1 (fr)
CN (2) CN102388068B (fr)
AR (1) AR075882A1 (fr)
AU (1) AU2010226814B2 (fr)
CA (2) CA2851737C (fr)
CL (3) CL2011002306A1 (fr)
CO (1) CO6501170A2 (fr)
CR (1) CR20110544A (fr)
EA (1) EA034783B1 (fr)
ES (1) ES2751946T3 (fr)
HK (1) HK1168116A1 (fr)
IL (4) IL214868A (fr)
JO (1) JO3615B1 (fr)
MA (1) MA33213B1 (fr)
MX (4) MX357213B (fr)
MY (2) MY162752A (fr)
NZ (1) NZ595464A (fr)
PE (2) PE20120497A1 (fr)
SG (3) SG174344A1 (fr)
TN (1) TN2011000433A1 (fr)
TW (2) TWI466681B (fr)
UY (1) UY32501A (fr)
WO (1) WO2010107752A2 (fr)
ZA (1) ZA201107279B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108969469A (zh) * 2011-05-02 2018-12-11 米伦纽姆医药公司 抗α4β7抗体的制剂
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
EP2782599B1 (fr) * 2011-11-23 2019-10-16 Amgen Inc. Administration d'un anticorps spécifique hétérodimère anti-alpha-4-bêta-7
DK3489261T3 (da) 2012-08-24 2020-12-14 Univ California Antistoffer og vacciner til anvendelse ved behandling af ror1-cancere og hæmning af metastase
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
AU2014318017B2 (en) 2013-09-05 2020-02-06 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
PT3112462T (pt) * 2014-02-28 2019-02-08 Astellas Pharma Inc Novos anticorpos biespecíficos ligando a tlr2 humano e tlr4 humano
EP3143404B1 (fr) 2014-05-16 2018-08-29 Amgen Inc. Dosage pour la détection de populations de cellules th1 et th2
WO2016028523A2 (fr) 2014-08-22 2016-02-25 Sorrento Therapeutics, Inc. Protéines de fixation antigénique fixant le cxcr3
EP3204424B1 (fr) 2014-10-06 2023-11-29 ChemoCentryx, Inc. Polythérapie à base d'inhibiteurs du récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7 pour le traitement d'une maladie inflammatoire de l'intestin
EP3581585A1 (fr) 2014-11-26 2019-12-18 Millennium Pharmaceuticals, Inc. Vedolizumab pour le traitement de la fistulisation de la maladie de crohn
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
CA2994412A1 (fr) * 2015-07-31 2017-02-09 Memorial Sloan-Kettering Cancer Center Proteines de liaison d'antigene ciblant cd56 et leurs utilisations
SG11201800864XA (en) * 2015-08-11 2018-03-28 Univ Osaka Antibody
JP2019512493A (ja) 2016-03-14 2019-05-16 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 移植片対宿主病の処置または予防の方法
CN116327920A (zh) * 2016-03-14 2023-06-27 千禧制药公司 预防移植物抗宿主疾病的方法
KR102039189B1 (ko) * 2016-03-23 2019-11-01 서울대학교산학협력단 중증열성혈소판감소증후군 바이러스의 외막 당단백질에 결합하는 항체 및 이의 용도
WO2017165742A1 (fr) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Procédés de traitement d'événements indésirables liés à l'immunité gastro-intestinale dans des polythérapies anti-ctla4 et anti-pd-1
EP3433275A1 (fr) 2016-03-24 2019-01-30 Millennium Pharmaceuticals, Inc. Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
WO2017184619A2 (fr) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Anticorps agonistes se liant au cd40 humain et leurs utilisations
CN109414502A (zh) 2016-06-12 2019-03-01 千禧制药公司 治疗炎症性肠病的方法
WO2018005519A2 (fr) 2016-06-27 2018-01-04 The Regents Of The University Of California Associations médicamenteuses pour le traitement du cancer
EP3596225A1 (fr) 2017-03-14 2020-01-22 Amgen Inc. Contrôle des glycoformes afucosylées totales d'anticorps produits en culture cellulaire
KR20190141148A (ko) 2017-04-28 2019-12-23 밀레니엄 파머슈티컬스 인코퍼레이티드 소아 장애를 치료하는 방법
CN111954719A (zh) 2018-03-26 2020-11-17 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型
AU2020355251A1 (en) 2019-09-26 2022-04-21 Amgen Inc. Methods of producing antibody compositions
AU2021227687B2 (en) 2020-02-26 2023-02-23 Vir Biotechnology, Inc. Antibodies against SARS-CoV-2 and methods of using the same
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
CA3197930A1 (fr) 2020-10-15 2022-04-21 Amgen Inc. Glycanes relatifs non apparies dans des procedes de production d'anticorps
MX2023010340A (es) * 2021-03-12 2024-01-12 Icahn School Med Mount Sinai Anticuerpos monoclonales neutralizantes de virus bk.
EP4352094A1 (fr) 2021-06-07 2024-04-17 Amgen Inc. Utilisation de fucosidase pour contrôler le taux d'afucosylation de protéines glycosylées
CA3233279A1 (fr) 2021-10-05 2023-04-13 Amgen Inc. Liaison de recepteur fc-gamma et teneur en glycane
WO2023215725A1 (fr) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US714785A (en) 1901-07-03 1902-12-02 Benjamin M Davis Disinfecting apparatus.
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
ATE160379T1 (de) 1990-10-29 1997-12-15 Chiron Corp Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
AU678787B2 (en) 1992-10-23 1997-06-12 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
JP4115517B2 (ja) 1994-01-25 2008-07-09 エラン ファーマシューティカルズ， インコーポレイテッド 白血球付着分子 ｖｌａ−４に対するヒト化抗体
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) * 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
AU7676300A (en) * 1999-10-12 2001-04-23 Cambridge Antibody Technology Limited Human anti-adipocyte monoclonal antibodies and their use
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
WO2002076406A2 (fr) * 2001-03-27 2002-10-03 Gershwin M Eric Anticorps contre autoantigenes de cirrhose biliaire primaire et methodes de preparation et d'utilisations associees
WO2002078779A1 (fr) * 2001-03-27 2002-10-10 Zeon Corporation Fil-guide medical
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
EP1542724A4 (fr) * 2002-08-19 2005-10-19 Abgenix Inc Anticorps diriges contre la proteine chimioattractive monocytaire 1 (mcp-1) et leurs utilisations
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
MX350383B (es) * 2004-01-09 2017-09-04 Pfizer Anticuerpos contra madcam.
WO2006017538A2 (fr) * 2004-08-03 2006-02-16 Dyax Corp. Proteines de liaison a la proteine hk1
US20070098715A1 (en) 2005-03-25 2007-05-03 Seth Ettenberg Antibodies against the tenascin major antigens
US7480268B2 (en) 2005-07-28 2009-01-20 Symbol Technologies, Inc. System and method for multiprotocol wireless communication
CA2629147A1 (fr) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. Immunoglobuline humanisee reactive avec l'integrine .alpha.4.beta.7
US7910703B2 (en) * 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use

Also Published As

Publication number Publication date
SG174344A1 (en) 2011-11-28
EP2408816B1 (fr) 2019-09-04
CL2011002306A1 (es) 2012-01-13
MX357213B (es) 2018-06-29
NZ595464A (en) 2013-08-30
TWI477511B (zh) 2015-03-21
JP2014140372A (ja) 2014-08-07
EP2408816A2 (fr) 2012-01-25
CA2754113C (fr) 2014-08-05
CN102388068A (zh) 2012-03-21
KR101391472B1 (ko) 2014-05-07
MA33213B1 (fr) 2012-04-02
IL232009A (en) 2015-11-30
IL232008A (en) 2015-11-30
IL214868A (en) 2015-08-31
US20120177662A1 (en) 2012-07-12
CN102388068B (zh) 2015-05-20
IL232009A0 (en) 2014-05-28
IL239965A0 (en) 2015-08-31
IL232008A0 (en) 2014-05-28
JP5775615B2 (ja) 2015-09-09
CO6501170A2 (es) 2012-08-15
IL214868A0 (en) 2011-11-30
JO3615B1 (ar) 2020-08-27
HK1168116A1 (en) 2012-12-21
UY32501A (es) 2010-04-30
JP5498566B2 (ja) 2014-05-21
ES2751946T3 (es) 2020-04-02
WO2010107752A2 (fr) 2010-09-23
TWI466681B (zh) 2015-01-01
EA201171148A1 (ru) 2012-04-30
US8454961B2 (en) 2013-06-04
MY162752A (en) 2017-07-14
MX2011009897A (es) 2011-12-08
CL2014000400A1 (es) 2014-08-29
PE20120497A1 (es) 2012-05-14
TW201418281A (zh) 2014-05-16
ZA201107279B (en) 2012-12-27
US20170275365A1 (en) 2017-09-28
CN103382222B (zh) 2016-12-28
AU2010226814B2 (en) 2013-05-16
CR20110544A (es) 2011-12-07
US20150086563A1 (en) 2015-03-26
US20100254975A1 (en) 2010-10-07
JP2012520679A (ja) 2012-09-10
US20130302354A1 (en) 2013-11-14
US8454962B2 (en) 2013-06-04
CA2754113A1 (fr) 2010-09-23
US20120183561A1 (en) 2012-07-19
MX357211B (es) 2018-06-29
US8871490B2 (en) 2014-10-28
KR20110128948A (ko) 2011-11-30
PE20160553A1 (es) 2016-05-18
SG10201801337WA (en) 2018-03-28
AR075882A1 (es) 2011-05-04
EA034783B1 (ru) 2020-03-20
CA2851737C (fr) 2019-01-08
CA2851737A1 (fr) 2010-09-23
US9499620B2 (en) 2016-11-22
KR20130067314A (ko) 2013-06-21
MX338969B (es) 2016-05-06
WO2010107752A3 (fr) 2011-01-20
KR101346530B1 (ko) 2013-12-31
IL239965A (en) 2016-10-31
CN103382222A (zh) 2013-11-06
SG10201400798VA (en) 2014-07-30
JP2015214563A (ja) 2015-12-03
US8444981B2 (en) 2013-05-21
MX2014013424A (es) 2015-07-29
JP5980384B2 (ja) 2016-08-31
MY184957A (en) 2021-04-30
CL2014000401A1 (es) 2014-08-29
AU2010226814A1 (en) 2011-09-29
TW201036626A (en) 2010-10-16

Similar Documents

Publication Publication Date Title
TN2011000433A1 (en) Alpha -4-beta-7heterodimer specific antagonist antibody
PH12014502527A1 (en) St2 antigen binding proteins
WO2010145792A8 (fr) Protéines bispécifiques se liant à un antigène
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
HK1174645A1 (en) Bispecific, tetravalent antigen binding proteins
ZA201207211B (en) Antibodies with ph dependent antigen binding
PH12013502205A1 (en) Antibodies to il-6 and their uses
SG10201401681PA (en) Novel antigen binding proteins
EP2552967A4 (fr) Protéines de fusion liantes, conjugués protéines de fusion liantes-médicaments, conjugués xten-médicaments et procédés pour les préparer et les utiliser
TN2014000120A1 (en) Cd27l antigen binding proteins
HK1215954A1 (zh) 蛋白、核酸、和抗體及其用途
EP2525822A4 (fr) Immunorégulation par des anticorps anti-ilt5 et fragments d'anticorps se liant à ilt5
MX2013013832A (es) Proteínas de unión receptoras fc.
PH12016500275B1 (en) Antibodies
MX340683B (es) Anticuerpos anti-vla-4.
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
WO2013181576A3 (fr) Méthodes d'évaluation et de fabrication de produits biologiques
WO2010136483A3 (fr) Protéines de liaison à l'antigène
UA104311C2 (ru) Антитело-антагонист, специфическое для гетеродимера альфа-4-бета-7
IL266073B (en) Heterodimeric antibody fccontaining proteins and methods for production thereof
WO2012122125A3 (fr) Compositions et procédés ciblant la génération de force dans les kinésines